Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23320330 | 0.92 | PKM (0.30) | PKM | |
| SCHEMBL21847224 | 0.86 | ALDH1A1 (0.41) | PKMNAMPTMEN1KMT2A | |
| SCHEMBL21847293 | 0.83 | GSK3B (0.38) | PKMMEN1KMT2A | |
| SCHEMBL21847258 | 0.81 | GSK3B (0.37) | PKMNAMPTMEN1KMT2A | |
| SCHEMBL21847215 | 0.79 | P2RX7 (0.44) | PKMMEN1KMT2A | |
| SCHEMBL23320236 | 0.79 | BRD4 (0.31) | BRD4MEN1KMT2A | |
| SCHEMBL21847212 | 0.78 | ALDH1A1 (0.39) | PKMNAMPTMEN1KMT2A | |
| SCHEMBL21847195 | 0.78 | KDM4E (0.41) | PKMMEN1KMT2A | |
| SCHEMBL21847188 | 0.77 | MEN1 (0.38) | BRD4PKMMEN1KMT2A | |
| SCHEMBL21847214 | 0.77 | P2RX7 (0.42) | PKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130367-A1 | 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE | BRD4, BRD3, BRD2 | BRD4 1/4885PKM 4530/4885NAMPT 2539/4885 |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | BRD4, BRD3, BRD2 | BRD4 1/4885PKM 4530/4885NAMPT 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.